Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn about a recent article by L. Garrigós, et al, published in ESMO Annals of Oncology:
“Simultaneous publication with ESMOBreast26
PHERGain-2 study!
T-DXd-THP continues to impress in the neoadjuvant setting!
DESTINY-Breast11 results show consistent reduction in residual cancer burden across all clinical subgroups (+/- nodal, HR+/-). A powerful addition to the pCR landscape.”
Title: A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study
Authors: L. Garrigós, M. Ruiz-Borrego, J.M. Pérez-García, A. Guerrero-Zotano, A. Cortés-Salgado, S. Kuemmel, M. Colleoni, C. Reboredo-Rendo, B. Bermejo, I. Blancas, J. Gavila, A. Fabi, C. Morales, A. Stradella, V. Carañana, E. Martínez-de Dueñas, C. Albacar, O. Ballesteros-Cidras, G. Martrat, S. Iacobucci, O. Boix, P. Berenguer-Molins, D. Alcalá-López, J. Cortés, A. Llombart-Cussac
Read the Full Article on ESMO Annals of Oncology
More posts featuring Elvina Almuradova.
